Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice

被引:129
作者
Proietti, E [1 ]
Greco, G [1 ]
Garrone, B [1 ]
Baccarini, S [1 ]
Mauri, C [1 ]
Venditti, M [1 ]
Carlei, D [1 ]
Belardelli, F [1 ]
机构
[1] Ist Super Sanita, Virol Lab, I-00161 Rome, Italy
关键词
cyclophosphamide; adoptive immunotherapy; interferon type I; tumors; mouse;
D O I
10.1172/JCI1348
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cyclophosphamide (CTX) increases the antitumor effectiveness of adoptive immunotherapy in mice, and combined immunotherapy regimens are now used in some clinical trials. However, the mechanisms underlying the synergistic antitumor responses are still unclear. The purpose of this study was (a) to evaluate the antitumor response to CTX and adoptive immunotherapy in mice bearing four different syngeneic tumors (two responsive in vivo to CTX and two resistant); and (b) to define the mechanism(s) of the CTX-immunotherapy synergism. Tumor-bearing DBA/2 mice were treated with a single injection of CTX followed by an intravenous infusion of tumor-immune spleen cells. In all the four tumor models, a single CTX injection resulted in an impressive antitumor response to the subsequent injection of spleen cells from mice immunized with homologous tumor cells independently of the in vivo response to CTX alone. Detailed analysis of the antitumor mechanisms in mice transplanted with metastatic Friend leukemia cells revealed that (a) the effectiveness of this combined therapy was dependent neither on the CTX-induced reduction of tumor burden nor on CTX-induced inhibition of some putative tumor-induced suppressor cells; (b) the CTX/immune cells' regimen strongly protected the mice from subsequent injection of FLC, provided the animals were also preinoculated with inactivated homologous tumor together with the immune spleen cells; (c) CD4(+) T immune lymphocytes were the major cell type responsible for the antitumor activity; (d) the combined therapy was ineffective in mice treated with antiasialo-GM(1) or anti-IFN-alpha/beta antibodies; (e) spleen and/or bone marrow cells from CTX-treated mice produced soluble factors that assisted in proliferation of the spleen cells. Altogether, these results indicate that CTX acts via bystander effects, possibly through production of T cell growth factors occurring during the rebound events after drug administration, which may sustain the proliferation, survival, and activity of the transferred immune T lymphocytes. Thus, our findings indicate the need for reappraisal of the mechanisms underlying the synergistic effects of CTX and adoptive immunotherapy, and may provide new insights into the definition of new and more effective strategies with chemotherapy and adoptive immunotherapy for cancer patients.
引用
收藏
页码:429 / 441
页数:13
相关论文
共 56 条
[11]  
GABRIELE L, 1995, INVAS METAST, V13, P147
[12]   REGULATION OF SPECIFIC CELL-MEDIATED CYTOTOXIC RESPONSE AGAINST SV40-INDUCED TUMOR ASSOCIATED ANTIGENS BY DEPLETION OF SUPPRESSOR T-CELLS WITH CYCLOPHOSPHAMIDE IN MICE [J].
GLASER, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1979, 149 (03) :774-779
[13]   ADOPTIVE CHEMOIMMUNOTHERAPY USING EX-VIVO ACTIVATED MEMORY T-CELLS AND CYCLOPHOSPHAMIDE - TUMOR LYSIS SYNDROME OF A METASTATIC SOFT-TISSUE SARCOMA [J].
GOLD, JE ;
MALAMUD, SC ;
LAROSA, F ;
OSBAND, ME .
AMERICAN JOURNAL OF HEMATOLOGY, 1993, 44 (01) :42-47
[14]   AUTOLYMPHOCYTE THERAPY .1. IN-VIVO TUMOR-SPECIFIC ADOPTIVE CELLULAR THERAPY OF MURINE MELANOMA AND CARCINOMA USING EX-VIVO ACTIVATED MEMORY T-LYMPHOCYTES [J].
GOLD, JE ;
OSBAND, ME .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (12) :1871-1882
[15]   ADOPTIVE TRANSFER OF EX-VIVO ACTIVATED MEMORY T-CELLS WITH OR WITHOUT CYCLOPHOSPHAMIDE FOR ADVANCED METASTATIC MELANOMA - RESULTS IN 36 PATIENTS [J].
GOLD, JE ;
ROSS, SD ;
KRELLENSTEIN, DJ ;
LAROSA, F ;
MALAMUD, SC ;
OSBAND, ME .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (05) :698-708
[16]   ADOPTIVE TRANSFER OF EX VIVO-ACTIVATED MEMORY T-CELL SUBSETS WITH CYCLOPHOSPHAMIDE PROVIDES EFFECTIVE TUMOR-SPECIFIC CHEMOIMMUNOTHERAPY OF ADVANCED METASTATIC MURINE MELANOMA AND CARCINOMA [J].
GOLD, JE ;
ZACHARY, DT ;
OSBAND, ME .
INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (04) :580-586
[17]   ADOPTIVELY TRANSFERRED EX-VIVO ACTIVATED MEMORY T-CELLS WITH CYCLOPHOSPHAMIDE - EFFECTIVE TUMOR-SPECIFIC CHEMOIMMUNOTHERAPY OF ADVANCED METASTATIC MURINE MELANOMA AND CARCINOMA [J].
GOLD, JE ;
ZACHARY, DT ;
OSBAND, ME .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1994, 73 (01) :115-122
[18]   AUTOLYMPHOCYTE THERAPY .2. DEPENDENCE OF IN-VIVO ANTITUMOR SPECIFICITY AND LONG-TERM IMMUNITY AGAINST MURINE MELANOMA AND CARCINOMA ON EX-VIVO ACTIVATED DONOR MEMORY T-CELLS [J].
GOLD, JE ;
OSBAND, ME .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1994, 71 (03) :325-332
[19]  
GRECO G, 1995, INT J CANCER, V61, P1
[20]   THERAPY OF DISSEMINATED MURINE LEUKEMIA WITH CYCLOPHOSPHAMIDE AND IMMUNE LYT-1+,2- T-CELLS - TUMOR-ERADICATION DOES NOT REQUIRE PARTICIPATION OF CYTO-TOXIC T-CELLS [J].
GREENBERG, PD ;
KERN, DE ;
CHEEVER, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1985, 161 (05) :1122-1134